Arena Life Science
Rivaroxaban is a highly selective direct factor Xa inhibitor with high oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi.
• Axabin 2.5mg, co-administered with low dose Aspirin (75– 100 mg) alone or with ASA plus clopidogrel, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers
• Axabin 2.5mg, co-administered with low dose Aspirin (75– 100 mg), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischemic events.
No 20, 5th Floor , 8th Sharestan , Makoueipour St, Za'feraniyeh, Tehran-Iran
Phone: (+98) 21 26 80 5483 - 21 26 80 5489 - Fax: (+98)21 26 80 5478 Email: email@example.com
All rights of this website belong to Arena Life Science